Earnings Forecast Research on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated has received $0.02 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $0.01 while the top line estimate is $0.03 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 0%.

Corcept Therapeutics Incorporated reported better than expected with a surprise EPS of 100% or $0.01 during its most recent quarterly earnings. The Actual EPS was $0.02 compared to the Estimated EPS of $0.01.

In the last quarter, Corcept Therapeutics Incorporated reported Annual Earnings of $0.02. Based on the filings, last years Annual Earnings was, $-0.03. In the last Quarter, CORT reported a surprise Earnings per Share of 100% . The consensus estimate for current quarter is $0.02 and for the current fiscal year, the estimate is $0.05. For the Next fiscal year, the estimate is $0.29 based on the consensus.

Corcept Therapeutics Incorporated (NASDAQ:CORT) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.29 points or 3.92% at $7.11 with 1,388,426 shares getting traded. Post opening the session at $7.19, the shares hit an intraday low of $6.7 and an intraday high of $7.35 and the price was in this range throughout the day. The company has a market cap of $789 million and the number of outstanding shares has been calculated to be 111,031,762 shares. The 52-week high of Corcept Therapeutics Incorporated (NASDAQ:CORT) is $10 and the 52-week low is $3.27.

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.


Share this post

Leave a Reply